Idera Pharmaceuticals, Inc.
IDRA
NASDAQ0.42
Idera Pharmaceuticals, Inc.
NASDAQ:IDRA
RECENT
PRICE
0.42
P/E
RATIO
-0.08
(PEG:- -)
P/E RATIO
RELATIVE
TO S&P
-0.00
DIV
YLD
0.00%
High:
Low:
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Legends
Stock price
1.30 Beta (1.0 Market)
0
0
0
0
0
0
0
0
0
% total return 02/23:
Stock
S&P
1y.
0
0
3y.
0
0
5y.
0
0
0
Percent shares traded:
0
0
0
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Fiscal year
1.17
(7.95)
1.21
- -
3.01
(4.98)
(6.56)
- -
9.31
0.53
8.18
- -
11.79
2.58
(5.37)
- -
5.13
(5.72)
(6.25)
- -
0.02
(6.89)
(5.56)
- -
0.01
(5.57)
(5.76)
0.17
0.01
(3.32)
(3.12)
0.19
0.01
(3.73)
(3.13)
0.08
0.02
(3.38)
(3.04)
- -
1.02
(2.41)
(1.79)
- -
0.05
(3.35)
(2.82)
- -
0.02
(2.25)
(1.95)
- -
0.05
(1.98)
(1.56)
- -
- -
(3.33)
(1.00)
- -
- -
2.90
(0.73)
- -
0.00
(0.32)
(0.29)
- -
Revenue per share
Earnings per share
Free Cash Flow per sh
Dividends per share
0.04
5.89
0.62
2.91
0.14
7.83
0.04
11.31
0.03
10.53
0.01
3.48
- -
1.92
0.00
5.91
0.11
4.19
0.05
5.81
0.03
6.48
0.01
5.47
0.00
2.41
0.00
(0.39)
0.00
(2.70)
- -
0.87
- -
0.46
CAPEX per share
Book Value per share
2
3
3
3
3
3
3
5
10
14
16
20
27
29
34
34
53
Comm.Shares outs.(m)
- -
- -
- -
(241.7)
(13.9)
- -
2,911.3
135.7
- -
337.9
4.8
- -
(98.5)
(4.8)
- -
(42.0)
(2.6)
- -
(28.1)
(1.9)
0.1%
(56.5)
(3.3)
0.1%
(125.9)
(6.9)
0.0%
(147.4)
(7.4)
- -
(106.1)
(4.8)
- -
(79.1)
(3.4)
- -
(85.4)
(3.4)
- -
(23.1)
(1.0)
- -
(12.0)
(0.3)
- -
11.1
0.4
- -
(0.1)
(0.0)
- -
Avg. annual P/E ratio
P/E relative to S&P500
Avg. annual div. yield
Capital Structure (30/9/22 | Q3)
Total liabilities
$83 m.
Total assets
$104 m.
Long-term debt
$0 m.
Cash and equiv.
$27 m.
Goodwill $10 m.
Retained earnings $(748) m.
Common stock 53 m. shares
Market Capitalisation
$27 m. (as of 6/2/23)
0
(48,783.0)%
0
(39,021.6)%
0
(38,657.4)%
0
(53,084.9)%
0
(19,616.9)%
16
(239.3)%
1
(7,368.8)%
1
(9,207.9)%
1
(3,181.4)%
- -
(Infinity)%
- -
(Infinity)%
0
(Infinity)%
Revenue (m)
Operating margin
0
(24)
0
(19)
0
(18)
0
(39)
0
(49)
1
(38)
1
(66)
0
(60)
0
(57)
0
(113)
0
98
0
(17)
Depreciation (m)
Net profit (m)
- -
(44,860.4)%
- -
(37,725.5)%
- -
(38,778.7)%
- -
(52,934.2)%
- -
(19,500.0)%
- -
(237.0)%
- -
(7,315.3)%
- -
(9,045.5)%
- -
(3,903.0)%
- -
(Infinity)%
- -
Infinity%
16.5%
(Infinity)%
Income tax rate
Net profit margin
19
- -
12
6
- -
7
26
- -
32
35
1
43
56
1
84
102
0
103
107
- -
108
64
- -
64
(8)
- -
(11)
34
- -
(91)
29
1
29
11
0
21
Working capital (m)
Long-term debt (m)
Equity (m)
(121.9)%
(92.9)%
(197.7)%
(287.5)%
(177.8)%
(290.3)%
(56.2)%
(49.4)%
(56.2)%
(87.1)%
(75.1)%
(89.0)%
(56.7)%
(52.5)%
(58.1)%
(36.9)%
(33.8)%
(37.1)%
(60.9)%
(55.7)%
(61.3)%
(93.5)%
(82.0)%
(93.6)%
804.1%
(119.0)%
506.0%
(318.5)%
(265.7)%
123.6%
327.0%
281.4%
333.0%
(22.3)%
(21.8)%
(80.4)%
ROIC
Return on capital
Return on equity
Working Capital
2019
2020
2021
Cash assets
43
36
35
Receivables
- -
- -
- -
Inventory
- -
- -
- -
Other
3
4
1
Current assets
46
41
34
Acc. Payable
0
0
1
Debt due
0
0
0
Other
54
7
4
Current liab.
55
7
5
100.0%
- -
103.0%
- -
105.8%
- -
102.1%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
0.6%
100.0%
- -
Plowback ratio
Div.&Repurch. to FCF
Idera Pharmaceuticals, Inc. (US) started trading on January 4, 1996 (cik: 0000861838), operates in the Healthcare sector (Biotechnology industry), has 13 full-time employees, and is led by Mr. Vincent Milano. Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.
Annual rates
(avg rate of change)
Past
5 y.
Past
10 y.
Revenues
- -
- -
Cash flow
-17.99%
10.82%
Earnings
-25.65%
8.97%
Dividends
- -
- -
Book value
106.51%
107.77%
Insider trading
Type
Shares
Date
Taylor John Clayton
Exempt
22,810
01/17/23
Taylor John Clayton
Exempt
1.34mln.
01/17/23
Kraus Carl N
Exempt
440,844
01/17/23
Salain Daniel
Exempt
22,810
01/17/23
Salain Daniel
Exempt
1.34mln.
01/17/23
Fiscal Year Ends
Quarterly Revenue (m)
Full fiscal year
I
II
III
IV
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
0
- -
- -
Fiscal Year Ends
Earnings per share
Full fiscal year
I
II
III
IV
2020
0.26
(0.72)
(0.61)
(2.27)
-3.33
2021
3.42
(0.22)
(0.18)
(0.12)
2.90
2022
(0.08)
(0.10)
(0.06)
- -
- -
Fiscal Year Ends
Quarterly dividends paid
Full fiscal year
I
II
III
IV
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -